Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06718413

Myofascial Dysfunction in Post Stroke Shoulder Pain

Led by Johns Hopkins University · Updated on 2026-02-27

68

Participants Needed

1

Research Sites

178 weeks

Total Duration

On this page

Sponsors

J

Johns Hopkins University

Lead Sponsor

N

National Center for Complementary and Integrative Health (NCCIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Shoulder pain is extremely common after stroke and occurs in 30-70% of patients. The pain may begin as early as one week after stroke, although peak onset and severity occurs around four months, and persists into the chronic stage. Chronic post stroke shoulder pain (PSSP) interferes with motor recovery, decreases quality of life, and contributes to depression. PSSP is thought to be caused mainly by damage to the myofascial tissues around the shoulder joint. Interestingly, an MRI study in patients with PSSP showed that the degree of structural damage to the muscles did not correlate with the degree of pain. Thus, the pathophysiology of myofascial dysfunction and pain in PSSP has not been elucidated leading to missed opportunities for early diagnosis and variable success with pain management. The accumulation of hyaluronic acid (HA) in muscle and its fascia can cause myofascial dysfunction. HA is a glycosaminoglycan (GAG) consisting of long-chain polymers of disaccharide units of glucuronic acid and N-acetylglucosamine and is a chief constituent of the extracellular matrix of muscle. In physiologic quantities, HA functions as a lubricant and a viscoelastic shock absorber, enabling force transmission during contraction and stretch. Reduced joint mobility and spasticity result in focal accumulation and alteration of HA in muscle. This can lead to the development of stiff areas and taut bands, dysfunctional gliding of deep fascia and muscle layers, reduced range of motion (ROM), and pain. However, the association of muscle HA accumulation with PSSP has not been established. The investigators have quantified the concentration of HA in muscle using T1rho (T1ρ) MRI and found that T1ρ relaxation time is increased in post stroke shoulder pain and stiffness. Furthermore, dynamic US imaging using shear strain mapping can quantify dysfunctional gliding of muscle that may generate pain during ROM. Myofascial dysfunction can result in non-painful reduction in ROM (latent PSSP), which may become painful due to episodic overuse injury producing greater shear dysfunction (active PSSP). Hence, shear strain mapping may differentiate between latent versus active PSSP. Thus, quantitative Motor Recovery (MR) and US imaging may serve as useful biomarkers to elucidate the pathophysiology of myofascial dysfunction.

CONDITIONS

Official Title

Myofascial Dysfunction in Post Stroke Shoulder Pain

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Hemiparesis resulting from ischemic or hemorrhagic stroke
  • Stroke occurred between 3 and 180 months ago
  • Difference of more than 10 degrees of passive external rotation range of motion between non-paretic and paretic shoulders, with or without pain
  • Ability to provide informed consent, HIPAA authorization, and comply with study procedures
Not Eligible

You will not qualify if you...

  • Use of Botulinum toxin or intrathecal baclofen for spasticity within the past 3 months, phenol injections within the past 12 months, or ongoing changes in anti-spastic medications
  • Other neurological conditions affecting motor response such as Parkinson's disease, ALS, or MS
  • Significant cognitive impairment with a Mini Mental Status Examination score below 19 or positive depression screening on PHQ-9
  • Pregnancy
  • Known allergy to hyaluronidase
  • Standard MRI contraindications
  • Non-musculoskeletal post stroke shoulder pain such as central pain or chronic regional pain syndrome
  • Any condition preventing completion of the study as determined by the principal investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Johns Hopkins University

Baltimore, Maryland, United States, 21287

Actively Recruiting

Loading map...

Research Team

N

Ning Cao, MD

CONTACT

P

Preeti Raghavan

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here